Navigation Links
Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance
Date:2/26/2009

PALO ALTO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.4 million, or $0.01 per share, for the three months ended December 31, 2008, compared with a net loss of $12.9 million, or $0.25 per share, for the same period in 2007. For the twelve months ended December 31, 2008, Telik reported a net loss of $31.8 million, or $0.60 per share, compared with a net loss of $55.2 million, or $1.05 per share, for the year ended December 31, 2007. The results for the three and twelve months ended December 31, 2008 included an unrealized net gain of $4.6 million and $0.7 million, respectively, due to changes in fair value of investments and related rights. As of December 31, 2008, cash, cash equivalents, restricted cash and investments totaled $63.5 million.

Total research and development expenses (R&D) in the fourth quarter of 2008 were $2.7 million, compared to $8.8 million for the same period in 2007. Total R&D expense for the twelve months ended December 31, 2008, were $24.0 million, compared to $43.0 million for the same period in 2007. The decrease in R&D expenses in fourth quarter and full year 2008, compared to the comparable periods in 2007, was primarily due to a decrease in clinical development expenditures related to TELCYTA.

Total general and administrative expenses (G&A) for the fourth quarter of 2008 were $2.6 million, compared to $4.6 million for the same period in 2007. The decrease in G&A expenses, compared to the same period in 2007, was primarily due to a decrease in personnel related expenses. Total G&A expense for the twelve months ended December 31, 2008, was $10.6 million, compared to $15.9 million for the same period in 2007. The decrease in G&A expenses in 2008, compared to the same period in 2007, was primarily due to a decrease in personnel related expenses and legal expenses.

In February 2009, Telik announced a reorganization to focus resources on its most advanced preclinical and clinical development programs. The reorganization will enable the company to continue development of TELINTRA(R) and Telik's two leading preclinical oncology drug candidates: a cytotoxic prodrug, TLK58747, and dual Aurora-VEGFR inhibitor, TLK60404. The company also plans to continue to support the TRAP(R) technology collaborations.

The company's lead compound, TELINTRA, is a modified glutathione analog currently being evaluated in two Phase 2 studies for Myelodysplastic Syndrome (MDS) and Chemotherapy Induced Neutropenia (CIN). The company also plans to initiate a Phase 2 Study in Severe Chronic Idiopathic Neutropenia (SCIN) this year. The company will pursue a corporate partnership for the further development and commercialization of TELINTRA.

In the fourth quarter, the top-line results from the ASSIST-5 trial of TELCYTA(R), in combination with pegylated liposomal doxorubicin (PDL) versus PDL alone, as second line therapy in platinum refractory, primary or secondary platinum resistant ovarian cancer were announced, and the company plans to present the full data at an upcoming scientific meeting.

Telik also announced its financial guidance for 2009. The company anticipates its 2009 net cash utilization to be in the range of $26.0 million to $28.0 million, with total operating expenses in the range of $28.0 million to $30.0 million of which approximately 65% is expected to be R&D expense and 35% G&A expense. In 2009, Telik will focus its resources on 1) advancing the clinical development of TELINTRA in MDS and CIN, 2) initiating a trial of TELINTRA in SCIN, 3) advancing its two leading preclinical oncology drug candidates: a cytotoxic prodrug, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404, 4) supporting TRAP research collaborations, and 5) pursuing corporate partnerships for development of our drug product candidates.

Conference Call and Webcast

Telik will conduct its quarterly conference call today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). The conference call will be accessible via Telik's website at www.telik.com or by telephone at 800-288-8974 or 612-332-0226. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 985835. The archive will be available from approximately 6:30 p.m. Eastern time on February 26 through March 19, 2009.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

This press release contains "forward-looking" statements, including statements regarding Telik's financial guidance and expected cash utilization for 2009 and the future development of TELINTRA, TELCYTA, TLK58747 and TLK60404, support of TRAP research collaborations and potential corporate partnerships. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if the further development of TELINTRA, TELCYTA, TLK58747 or TLK60404, including any clinical trial of TELINTRA or TELCYTA, is delayed or unsuccessful, Telik's business would suffer; Telik's business would be adversely affected if it is unable to secure partners or raise funding for the continued development of its product candidates; if Telik's competitors develop and market products that are more effective than its product candidates or any product that Telik may develop, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated; and if Telik does not obtain regulatory approval to market products in the United States and foreign countries, Telik will not be permitted to commercialize its product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended September 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

                                 Telik, Inc.
                           Statements of Operations
                   (In thousands, except per share amounts)
                                 (Unaudited)


                                      Three Months
                                          Ended       Twelve Months Ended
                                      December 31,       December 31,
                                      ------------       ------------
                                      2008      2007      2008      2007
                                      ----      ----      ----      ----

    Operating costs and expenses:
      Research and
       development                  $2,701    $8,832   $23,952   $43,032
      General and
       administrative                2,552     4,649    10,560    15,941
      Restructuring costs               (3)        -       196     1,356
                                     ------   ------    ------    ------
        Total operating costs and
         expenses                    5,250    13,481    34,708    60,329
                                     ------   ------    ------    ------

    Loss from operations            (5,250)  (13,481)  (34,708)  (60,329)

    Interest and other income
     (expense), net                  4,873       560     2,945     5,114
                                     ------   ------    ------    ------
    Net loss                         $(377) $(12,921) $(31,763) $(55,215)
                                     ======  ========  ========  ========

    Basic and diluted net loss per
     share                          $(0.01)   $(0.25)   $(0.60)   $(1.05)
                                     ======    ======    ======    ======

    Weighted average shares used to
     calculate basic and diluted
      net loss per share             53,290    52,693    53,177    52,542
                                     ======    ======    ======    ======



           Selected Balance Sheet Data
                 (In thousands)
                   (Unaudited)

                     December 31,  December 31,
                           2008         2007
                           ----         ----

    Cash, cash
     equivalents,
     investments
     and
     restricted
     investments        $63,469      $93,233

    Total assets         75,413       98,528

    Stockholders'
     equity              62,372       87,319


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. Telik Announces Preclinical Presentations at AACR Annual Meeting
3. Telik Announces Patents on Compounds Related to TELINTRA
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: